Zeo ScientifiX 与 Pluri 达成战略协议，拓展美国制造与商业化平台
Zeo ScientifiX, Inc. (0001557376) (Filer)
Zeo ScientifiX 与 Pluri 于 10 月 26 日宣布达成最终战略协议，计划拓展双方服务再生医学、美学、健康与长寿市场的美国制造和商业化平台。Zeo ScientifiX 在 Form 8-K 中披露了该协议，并将联合新闻稿列为附件 99.1。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 26, 2026
ZEO SCIENTIFIX, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-55008 | 47-4180540 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
3321 College Avenue, Suite 246 |
33314 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (888) 963-7881
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.
Item 1.01 Entry into a Material Definitive Agreement.
On October 26, ZEO and Pluri Inc. (Nasdaq and TASE: PLUR) issued a joint press release announcing that they had entered into a definitive strategic agreement to expand the parties’ U.S. manufacturing and commercialization platform serving the regenerative medicine, aesthetics, wellness, and longevity markets.
A copy of the press release is included as Exhibit 99.1 to this Report.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Press Release, dated October 26, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: October 26, 2026 | ZEO SCIENTIFIX, INC. | |
| By: | /s/ Ian T. Bothwell | |
|
Ian T. Bothwell Chief Executive Officer and Chief Financial Officer | ||
2
来源：SEC EDGAR · 本站存档